



Sustained Release Ocular Drug Delivery Systems Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-26	121	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Sustained Release Ocular Drug Delivery Systems market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Sustained Release Ocular Drug Delivery Systems is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Sustained Release Ocular Drug Delivery Systems is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Sustained Release Ocular Drug Delivery Systems is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Sustained Release Ocular Drug Delivery Systems include Aciont Inc., Allergan, Envisia Therapeutics, GrayBug, Icon Bioscience, Innocore Pharmaceuticals, Neurotech Pharmaceuticals, Ocular Therapeutix and OHR Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Sustained Release Ocular Drug Delivery Systems market in terms of revenue (US\$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/W Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Sustained Release Ocular Drug Delivery Systems Market by Company

Aciont Inc.

Allergan

Envisia Therapeutics
GrayBug
Icon Bioscience
Innocore Pharmaceuticals
Neurotech Pharmaceuticals
Ocular Therapeutix
OHR Pharmaceuticals
PolyActiva
pSivida
TheraKine
Santen Pharmaceutical

Sustained Release Ocular Drug Delivery Systems Segment by Type

Microcapsules/Nanocapsules
Microspheres/Nanospheres
Liposome
Implants

Sustained Release Ocular Drug Delivery Systems Segment by Application

Glaucoma
Corneal Transplantation
Cataract
Others

Sustained Release Ocular Drug Delivery Systems Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sustained Release Ocular Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sustained Release Ocular Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sustained Release Ocular Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Sustained Release Ocular Drug Delivery Systems manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Sustained Release Ocular Drug Delivery Systems by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Sustained Release Ocular Drug Delivery Systems in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Sustained Release Ocular Drug Delivery Systems Market Size (2021-2032)
 - 2.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales (2021-2032)
 - 2.2.3 Global Sustained Release Ocular Drug Delivery Systems Market Average Price (2021-2032)
- 2.3 Sustained Release Ocular Drug Delivery Systems by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Microcapsules/Nanocapsules
 - 2.3.3 Microspheres/Nanospheres
 - 2.3.4 Liposome
 - 2.3.5 Implants
- 2.4 Sustained Release Ocular Drug Delivery Systems by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Glaucoma
 - 2.4.3 Corneal Transplantation
 - 2.4.4 Cataract
 - 2.4.5 Others

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Sustained Release Ocular Drug Delivery Systems Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sustained Release Ocular Drug Delivery Systems Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Sustained Release Ocular Drug Delivery Systems Revenue of Manufacturers (2021-2026)
- 3.4 Global Sustained Release Ocular Drug Delivery Systems Average Price by Manufacturers (2021-2026)
- 3.5 Global Sustained Release Ocular Drug Delivery Systems Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Product Type & Application
- 3.8 Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Established Date
- 3.9 Global Sustained Release Ocular Drug Delivery Systems Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Aciont Inc.
 - 4.1.1 Aciont Inc. Company Information
 - 4.1.2 Aciont Inc. Business Overview
 - 4.1.3 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)

- 4.1.4 Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio
- 4.1.5 Aciont Inc. Recent Developments
- 4.2 Allergan
 - 4.2.1 Allergan Company Information
 - 4.2.2 Allergan Business Overview
 - 4.2.3 Allergan Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.2.4 Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.2.5 Allergan Recent Developments
- 4.3 Envisia Therapeutics
 - 4.3.1 Envisia Therapeutics Company Information
 - 4.3.2 Envisia Therapeutics Business Overview
 - 4.3.3 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.3.4 Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.3.5 Envisia Therapeutics Recent Developments
- 4.4 GrayBug
 - 4.4.1 GrayBug Company Information
 - 4.4.2 GrayBug Business Overview
 - 4.4.3 GrayBug Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.4.4 GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.4.5 GrayBug Recent Developments
- 4.5 Icon Bioscience
 - 4.5.1 Icon Bioscience Company Information
 - 4.5.2 Icon Bioscience Business Overview
 - 4.5.3 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.5.4 Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.5.5 Icon Bioscience Recent Developments
- 4.6 Innocore Pharmaceuticals
 - 4.6.1 Innocore Pharmaceuticals Company Information
 - 4.6.2 Innocore Pharmaceuticals Business Overview
 - 4.6.3 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.6.4 Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.6.5 Innocore Pharmaceuticals Recent Developments
- 4.7 Neurotech Pharmaceuticals
 - 4.7.1 Neurotech Pharmaceuticals Company Information
 - 4.7.2 Neurotech Pharmaceuticals Business Overview
 - 4.7.3 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.7.4 Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.7.5 Neurotech Pharmaceuticals Recent Developments
- 4.8 Ocular Therapeutix
 - 4.8.1 Ocular Therapeutix Company Information
 - 4.8.2 Ocular Therapeutix Business Overview
 - 4.8.3 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
 - 4.8.4 Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio
 - 4.8.5 Ocular Therapeutix Recent Developments
- 4.9 OHR Pharmaceuticals

- 4.9.1 OHR Pharmaceuticals Company Information
- 4.9.2 OHR Pharmaceuticals Business Overview
- 4.9.3 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
- 4.9.5 OHR Pharmaceuticals Recent Developments

4.10 PolyActiva

- 4.10.1 PolyActiva Company Information
- 4.10.2 PolyActiva Business Overview
- 4.10.3 PolyActiva Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio
- 4.10.5 PolyActiva Recent Developments

4.11 pSivida

- 4.11.1 pSivida Company Information
- 4.11.2 pSivida Business Overview
- 4.11.3 pSivida Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio
- 4.11.5 pSivida Recent Developments

4.12 TheraKine

- 4.12.1 TheraKine Company Information
- 4.12.2 TheraKine Business Overview
- 4.12.3 TheraKine Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio
- 4.12.5 TheraKine Recent Developments

4.13 Santen Pharmaceutical

- 4.13.1 Santen Pharmaceutical Company Information
- 4.13.2 Santen Pharmaceutical Business Overview
- 4.13.3 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio
- 4.13.5 Santen Pharmaceutical Recent Developments

5 Global Sustained Release Ocular Drug Delivery Systems Market Scenario by Region

- 5.1 Global Sustained Release Ocular Drug Delivery Systems Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2021-2032
 - 5.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2021-2026
 - 5.2.2 Global Sustained Release Ocular Drug Delivery Systems Sales by Region: 2027-2032
- 5.3 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2021-2032
 - 5.3.1 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2021-2026
 - 5.3.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Region: 2027-2032
- 5.4 North America Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
 - 5.4.1 North America Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
 - 5.4.3 North America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
 - 5.5.1 Europe Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032

- 5.5.2 Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
- 5.5.3 Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
 - 5.7.1 South America Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
 - 5.7.3 South America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
 - 5.7.7 Colombia
- 5.8 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Market Size by Country: 2021 VS 2025 VS 2032
 - 5.8.2 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2032)
 - 5.8.4 Egypt
 - 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries

6 Segment by Type

- 6.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032)
 - 6.1.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032) & (W Units)
 - 6.1.2 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2032)
- 6.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021-2032)
 - 6.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2032) & (US\$ Million)
 - 6.2.2 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2032)

7 Segment by Application

7.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032)

7.1.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032) & (W Units)

7.1.2 Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2032)

7.2 Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021-2032)

7.2.1 Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2032) & (US\$ Million)

7.2.2 Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2032)

7.3 Global Sustained Release Ocular Drug Delivery Systems Price by Application (2021-2032)

8 Value Chain and Sales Channels Analysis of the Market

8.1 Sustained Release Ocular Drug Delivery Systems Value Chain Analysis

8.1.1 Sustained Release Ocular Drug Delivery Systems Key Raw Materials

8.1.2 Raw Materials Key Suppliers

8.1.3 Sustained Release Ocular Drug Delivery Systems Production Mode & Process

8.2 Sustained Release Ocular Drug Delivery Systems Sales Channels Analysis

8.2.1 Direct Comparison with Distribution Share

8.2.2 Sustained Release Ocular Drug Delivery Systems Distributors

8.2.3 Sustained Release Ocular Drug Delivery Systems Customers

9 Global Sustained Release Ocular Drug Delivery Systems Analyzing Market Dynamics

9.1 Sustained Release Ocular Drug Delivery Systems Industry Trends

9.2 Sustained Release Ocular Drug Delivery Systems Industry Drivers

9.3 Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges

9.4 Sustained Release Ocular Drug Delivery Systems Industry Restraints

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Sustained Release Ocular Drug Delivery Systems Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Sustained Release Ocular Drug Delivery Systems Sales (W Units) of Manufacturers (2021-2026)
- Table 7: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Sustained Release Ocular Drug Delivery Systems Revenue of Manufacturers (2021-2026)
- Table 9: Global Sustained Release Ocular Drug Delivery Systems Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Sustained Release Ocular Drug Delivery Systems Average Price (US\$/Unit) of Manufacturers (2021-2026)
- Table 11: Global Sustained Release Ocular Drug Delivery Systems Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Product Type & Application
- Table 14: Global Sustained Release Ocular Drug Delivery Systems Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Sustained Release Ocular Drug Delivery Systems by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Aciont Inc. Company Information
- Table 19: Aciont Inc. Business Overview
- Table 20: Aciont Inc. Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 21: Aciont Inc. Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 22: Aciont Inc. Recent Developments
- Table 23: Allergan Company Information
- Table 24: Allergan Business Overview
- Table 25: Allergan Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 26: Allergan Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 27: Allergan Recent Developments
- Table 28: Envisia Therapeutics Company Information
- Table 29: Envisia Therapeutics Business Overview
- Table 30: Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 31: Envisia Therapeutics Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 32: Envisia Therapeutics Recent Developments
- Table 33: GrayBug Company Information
- Table 34: GrayBug Business Overview
- Table 35: GrayBug Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 36: GrayBug Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 37: GrayBug Recent Developments
- Table 38: Icon Bioscience Company Information
- Table 39: Icon Bioscience Business Overview
- Table 40: Icon Bioscience Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 41: Icon Bioscience Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 42: Icon Bioscience Recent Developments
- Table 43: Innocore Pharmaceuticals Company Information
- Table 44: Innocore Pharmaceuticals Business Overview
- Table 45: Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 46: Innocore Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio

- Table 47: Innocore Pharmaceuticals Recent Developments
- Table 48: Neurotech Pharmaceuticals Company Information
- Table 49: Neurotech Pharmaceuticals Business Overview
- Table 50: Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 51: Neurotech Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 52: Neurotech Pharmaceuticals Recent Developments
- Table 53: Ocular Therapeutix Company Information
- Table 54: Ocular Therapeutix Business Overview
- Table 55: Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 56: Ocular Therapeutix Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 57: Ocular Therapeutix Recent Developments
- Table 58: OHR Pharmaceuticals Company Information
- Table 59: OHR Pharmaceuticals Business Overview
- Table 60: OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 61: OHR Pharmaceuticals Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 62: OHR Pharmaceuticals Recent Developments
- Table 63: PolyActiva Company Information
- Table 64: PolyActiva Business Overview
- Table 65: PolyActiva Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 66: PolyActiva Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 67: PolyActiva Recent Developments
- Table 68: pSivida Company Information
- Table 69: pSivida Business Overview
- Table 70: pSivida Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 71: pSivida Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 72: pSivida Recent Developments
- Table 73: TheraKine Company Information
- Table 74: TheraKine Business Overview
- Table 75: TheraKine Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 76: TheraKine Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 77: TheraKine Recent Developments
- Table 78: Santen Pharmaceutical Company Information
- Table 79: Santen Pharmaceutical Business Overview
- Table 80: Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Sales (W Units), Revenue (US\$ Million), Price (US\$/Unit) and Gross Margin (2021-2026)
- Table 81: Santen Pharmaceutical Sustained Release Ocular Drug Delivery Systems Product Portfolio
- Table 82: Santen Pharmaceutical Recent Developments
- Table 83: Global Sustained Release Ocular Drug Delivery Systems Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 84: Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2021-2026) & (W Units)
- Table 85: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Region (2021-2026)
- Table 86: Global Sustained Release Ocular Drug Delivery Systems Sales by Region (2027-2032) & (W Units)
- Table 87: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Region (2027-2032)
- Table 88: Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2021-2026) & (US\$ Million)
- Table 89: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2021-2026)
- Table 90: Global Sustained Release Ocular Drug Delivery Systems Revenue by Region (2027-2032) & (US\$ Million)
- Table 91: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Region (2027-2032)
- Table 92: North America Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 93: North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units)
- Table 94: North America Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units)
- Table 95: North America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US\$ Million)
- Table 96: North America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US\$ Million)
- Table 97: Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 98: Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units)
- Table 99: Europe Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units)
- Table 100: Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US\$ Million)
- Table 101: Europe Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US\$ Million)
- Table 102: Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US\$

Million)

- Table 103: Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units)
- Table 104: Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units)
- Table 105: Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US\$ Million)
- Table 106: Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US\$ Million)
- Table 107: South America Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 108: South America Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units)
- Table 109: South America Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units)
- Table 110: South America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US\$ Million)
- Table 111: South America Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US\$ Million)
- Table 112: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 113: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2021-2026) & (W Units)
- Table 114: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales by Country (2027-2032) & (W Units)
- Table 115: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2021-2026) & (US\$ Million)
- Table 116: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue by Country (2027-2032) & (US\$ Million)
- Table 117: Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2021-2026) & (W Units)
- Table 118: Global Sustained Release Ocular Drug Delivery Systems Sales by Type (2027-2032) & (W Units)
- Table 119: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2026)
- Table 120: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2027-2032)
- Table 121: Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2021-2026) & (US\$ Million)
- Table 122: Global Sustained Release Ocular Drug Delivery Systems Revenue by Type (2027-2032) & (US\$ Million)
- Table 123: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2026)
- Table 124: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2027-2032)
- Table 125: Global Sustained Release Ocular Drug Delivery Systems Price by Type (2021-2026) & (US\$/Unit)
- Table 126: Global Sustained Release Ocular Drug Delivery Systems Price by Type (2027-2032) & (US\$/Unit)
- Table 127: Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2021-2026) & (W Units)
- Table 128: Global Sustained Release Ocular Drug Delivery Systems Sales by Application (2027-2032) & (W Units)
- Table 129: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2026)
- Table 130: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2027-2032)
- Table 131: Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2021-2026) & (US\$ Million)
- Table 132: Global Sustained Release Ocular Drug Delivery Systems Revenue by Application (2027-2032) & (US\$ Million)
- Table 133: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2026)
- Table 134: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2027-2032)
- Table 135: Global Sustained Release Ocular Drug Delivery Systems Price by Application (2021-2026) & (US\$/Unit)
- Table 136: Global Sustained Release Ocular Drug Delivery Systems Price by Application (2027-2032) & (US\$/Unit)
- Table 137: Key Raw Materials
- Table 138: Raw Materials Key Suppliers
- Table 139: Sustained Release Ocular Drug Delivery Systems Distributors List
- Table 140: Sustained Release Ocular Drug Delivery Systems Customers List
- Table 141: Sustained Release Ocular Drug Delivery Systems Industry Trends
- Table 142: Sustained Release Ocular Drug Delivery Systems Industry Drivers
- Table 143: Sustained Release Ocular Drug Delivery Systems Industry Restraints
- Table 144: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Sustained Release Ocular Drug Delivery Systems Product Image
- Figure 5: Global Sustained Release Ocular Drug Delivery Systems Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Sustained Release Ocular Drug Delivery Systems Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Sustained Release Ocular Drug Delivery Systems Sales (2021-2032) & (W Units)
- Figure 8: Global Sustained Release Ocular Drug Delivery Systems Average Price (US\$/Unit) & (2021-2032)
- Figure 9: Microcapsules/Nanocapsules Product Image
- Figure 10: Microspheres/Nanospheres Product Image
- Figure 11: Liposome Product Image
- Figure 12: Implants Product Image
- Figure 13: Glaucoma Product Image

- Figure 14: Corneal Transplantation Product Image
- Figure 15: Cataract Product Image
- Figure 16: Others Product Image
- Figure 17: Global Sustained Release Ocular Drug Delivery Systems Revenue Share by Manufacturers in 2025
- Figure 18: Global Manufacturers of Sustained Release Ocular Drug Delivery Systems, Manufacturing Sites & Headquarters
- Figure 19: Global Top 5 and 10 Sustained Release Ocular Drug Delivery Systems Players Market Share by Revenue in 2025
- Figure 20: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 21: Global Sustained Release Ocular Drug Delivery Systems Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 22: Global Sustained Release Ocular Drug Delivery Systems Sales by Region in 2025
- Figure 23: Global Sustained Release Ocular Drug Delivery Systems Revenue by Region in 2025
- Figure 24: North America Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025
- Figure 25: North America Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032)
- Figure 26: North America Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032)
- Figure 27: United States Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 28: Canada Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 29: Mexico Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 30: Europe Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025
- Figure 31: Europe Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032)
- Figure 32: Europe Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032)
- Figure 33: Germany Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: France Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: U.K. Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Italy Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Russia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Spain Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Netherlands Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Switzerland Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 41: Sweden Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 42: Poland Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 43: Asia Pacific Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025
- Figure 44: Asia Pacific Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032)
- Figure 45: Asia Pacific Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032)
- Figure 46: China Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: Japan Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: South Korea Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: India Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Australia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: Taiwan Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 52: Southeast Asia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 53: Southeast Asia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 54: South America Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025
- Figure 55: South America Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032)
- Figure 56: South America Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032)
- Figure 57: Brazil Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 58: Argentina Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 59: Chile Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 60: Colombia Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Market Size by Country in 2025
- Figure 62: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Sales Market Share by Country (2021-2032)
- Figure 63: Middle East and Africa Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Country (2021-2032)
- Figure 64: Egypt Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: South Africa Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 66: Israel Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 67: Türkiye Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 68: GCC Countries Sustained Release Ocular Drug Delivery Systems Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 69: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Type (2021-2032)
- Figure 70: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Type (2021-2032)
- Figure 71: Global Sustained Release Ocular Drug Delivery Systems Price (US\$/Unit) by Type (2021-2032)
- Figure 72: Global Sustained Release Ocular Drug Delivery Systems Sales Market Share by Application (2021-2032)

- Figure 73: Global Sustained Release Ocular Drug Delivery Systems Revenue Market Share by Application (2021-2032)
- Figure 74: Global Sustained Release Ocular Drug Delivery Systems Price (US\$/Unit) by Application (2021-2032)
- Figure 75: Sustained Release Ocular Drug Delivery Systems Value Chain
- Figure 76: Sustained Release Ocular Drug Delivery Systems Production Mode & Process
- Figure 77: Direct Comparison with Distribution Share
- Figure 78: Distributors Profiles
- Figure 79: Sustained Release Ocular Drug Delivery Systems Industry Opportunities and Challenges